Milan, 1 February 2017 - Recordati S.p.A. will be hosting a meeting with the financial community and specialized press on:
Thursday 9 February 2017 at 4 pm
Palazzo Mezzanotte
Piazza degli Affari, 6 - Milan
At the meeting Recordati’s preliminary full year 2016 results will be presented and the Group’s development strategy and objectives for the period 2017-2019 will be discussed. The meeting will be held in English.
For those who are unable to attend the proceedings followed by a Q&A session will be available via conference call. Dial-in numbers are:
Italy +39 02 8058811, toll free 800 213 858
UK +44 1 212818003, toll free 800 0156384
USA +1 718 7058794, toll free 855 2656959
France +33 170918703
Germany +49 65 255114451
Callers are invited to dial-in 10 minutes before conference time. If conference operator assistance is required during the connection, please digit * followed by 0.
A set of slides which will be referred to during the call will be available on our website www.recordati.com under Investors/Company Presentations.
A recording of the conference call will be subsequently placed on the website www.recordati.com.
Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of around 4,000, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey, in North Africa, in the United States of America and in some Latin American countries. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties within the urogenital therapeutic area and of treatments for rare diseases. Consolidated revenue for 2015 was € 1,047.7 million, operating income was € 278.5 million and net income was € 198.8 million.
For further information:
Recordati website: www.recordati.com
Investor Relations Media Relations
Marianne Tatschke Studio Noris Morano
(39)0248787393 (39)0276004736, (39)0276004745
e-mail: inver@recordati.it e-mail: norismorano@studionorismorano.com
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/bdd4fab2-6191-49c4-a46c-22862f868827
